Valuation: Amplia Therapeutics Limited

Market Cap 66.73M 46.22M 40.61M 37.91M 34.79M 65.12M 4.43B 450M 176M 2.19B 174M 170M 7.57B P/E 2027 *
-5.65x
P/E 2028 * -21.7x
Enterprise Value 51.23M 35.48M 31.18M 29.1M 26.71M 50M 3.4B 345M 135M 1.68B 133M 130M 5.81B EV / Sales 2027 *
-
EV / Sales 2028 * 4.52x
Free-Float
90.48%
Yield 2027 *
-
Yield 2028 * -
1 day-3.85%
1 week-7.41%
Current month-13.79%
1 month-13.79%
3 months-16.67%
6 months-3.85%
Current year-16.67%
1 week 0.12
Extreme 0.125
0.14
1 month 0.12
Extreme 0.125
0.16
Current year 0.1
Extreme 0.1
0.28
1 year 0.1
Extreme 0.1
0.28
3 years 0.05
Extreme 0.049
0.42
5 years 0.05
Extreme 0.049
0.42
10 years 0.04
Extreme 0.045
18.3
Manager TitleAgeSince
Chief Executive Officer - 05/12/2022
Director of Finance/CFO - 01/10/2021
Chief Tech/Sci/R&D Officer - 12/05/2025
Director TitleAgeSince
Director/Board Member 70 02/09/2015
Chairman - 25/05/2018
Chairman - 30/06/2026
Date Insider Type Main position Quantity % Market Cap.
9/8/25 A Buy

Founder

86,957 0.0224%
9/8/25 A Free

Director

240,590 0.0620%
9/8/25 A Fiscal year

Chairman

750,000 0.1933%
Change 5-day change 1-year change 3-year change Capi.($)
-3.85%-7.41%-47.92%+43.68% 46.22M
+0.47%+2.27%+50.78%+70.84% 55.2B
+2.83%+0.48%+28.18%+82.59% 55.6B
+0.54%+1.22%-16.62%-13.47% 23.51B
-0.97%-3.30%-1.79%+383.00% 22.35B
-3.81%-3.31%+13.59%-13.97% 20.6B
-2.15%-2.30%+27.27%-31.03% 17.45B
-2.53%-7.00%+24.81%+541.96% 15.16B
-2.09%+0.64%+49.78%+178.74% 13.91B
-3.14%-8.47%+165.37%+292.18% 13.74B
Average -1.45%-1.52%+29.34%+153.45% 23.76B
Weighted average by Cap. -0.21%-0.52%+33.81%+128.96%

Financials

2027 *2028 *
Net sales - 10M 6.93M 6.09M 5.68M 5.21M 9.76M 663M 67.36M 26.34M 328M 26M 25.44M 1.13B
Net income -11.6M -8.03M -7.06M -6.59M -6.05M -11.32M -770M -78.14M -30.56M -381M -30.16M -29.51M -1.32B -3.6M -2.49M -2.19M -2.05M -1.88M -3.51M -239M -24.25M -9.48M -118M -9.36M -9.16M -409M
Net Debt -15.5M -10.74M -9.43M -8.81M -8.08M -15.13M -1.03B -104M -40.83M -509M -40.31M -39.43M -1.76B -21.5M -14.89M -13.08M -12.21M -11.21M -20.98M -1.43B -145M -56.64M -706M -55.91M -54.7M -2.44B
Logo Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Employees
-
Date Price Change Volume
30/07/26 A$0.1250 -3.85% 311,425
29/07/26 A$0.1300 0.00% 467,260
28/07/26 A$0.1300 0.00% 435,359
27/07/26 A$0.1300 -7.14% 422,486
24/07/26 A$0.1400 +3.70% 258,077
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1300AUD
Average target price
0.4200AUD
Spread / Average Target
+223.08%

Annual profits - Rate of surprise